Search Results
Your search for ,had matches 18596 pages
Showing 1 - 50I Have Advanced-Stage Lung Cancer. I Refuse to Be a Victim of the Disease
I remember thinking on the day I turned 60, May 10, 2021, “This is going to be the best year of my life.” I couldn’t have been more wrong. Within weeks of feeling that swell of optimism about my future, I began experiencing a series of odd, and, seemingly unrelated symptoms leading to my eventual...
Survival Among Patients Treated in Community Oncology Settings Compared With National Benchmarks From SEER Database
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) when treated at community oncology practices participating in the Flatiron Health Research Network had better or comparable survival compared with national benchmark survival estimates generated by the...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?
With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer,1 the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research fellow in Hematology-Oncology at Penn Medicine and colleagues have proposed an unorthodox...
Early Myocarditis After Immune Checkpoint Inhibitors Signals Elevated Mortality Risk
Early onset of immune checkpoint inhibitor (ICI)–related myocarditis is associated with increased mortality risk, as is the presence of concurrent major adverse cardiac events, according to results presented in a poster and at a press briefing during the 2026 American Association for Cancer...
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Patient-reported outcomes from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed...
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
On May 22, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2), for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for ...
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ...
Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer
Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to results from the prospective, randomized open-label phase II ARACOG (AFT-47) trial to be presented at...
GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings to be presented at the 2026 ASCO Annual Meeting (Abstract 3143). GLP-1 receptor expression ...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial that will be presented at the 2026 ASCO Annual Meeting (Abstract 12004). The analysis also suggested that...
Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer
Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results from a two-arm pilot randomized trial that will be presented by Marchetti at the 2026 ASCO Annual...
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. The researchers...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Study Shows Potential Missing Patient Information in SEER Database
A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)...
Patients With IBD May Be at Risk for VTE After Colorectal Cancer Surgery
Patients with inflammatory bowel disease (IBD) may be at a greater risk for postoperative venous thromboembolism (VTE) at least 30 days after surgery for colorectal cancer, according to the results of a large, retrospective study presented at the 2026 Digestive Disease Week Conference. “These...
Ficerafusp Alfa Plus Pembrolizumab: 2-Year Outcomes in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Hanna et al, the 2-year follow-up of the expansion cohort in a phase I/Ib trial indicates persistent benefit of first-line ficerafusp alfa plus pembrolizumab in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell...
How Conquering Cancer Is a Team Effort
After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. “My second day on active duty was September 11, 2001,” said Dr. Mittendorf. “I was an attending surgeon at Walter Reed Army Medical Center (now called...
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adult...
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA...
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer....
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
An international research team has shown that a specific subtype of diffuse large B-cell lymphoma (DLBCL) is associated with higher mortality risk in women than in men. The study was led by the laboratory of Ari Melnick, MD, Director of the Josep Carreras Leukaemia Research Institute and the Gebroe ...
Early Ovarian Cancer: Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
In a retrospective cohort study reported as a research letter in JAMA Oncology, Matsuo et al found an increasing use of minimally invasive surgery (MIS), an association of MIS with intraoperative capsule rupture, and an association of capsule rupture with poorer survival in patients with early...
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
FDA Approves Combination Regimen for Newly Diagnosed AML
On May 13, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine tablets (Inqovi) plus venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or who have comorbidities that preclude them from...
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
Hundreds of thousands of people diagnosed with cancer are still alive today, but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those diagnosed today to carry a germline...
Inherited Long Telomeres May Increase the Risk of Lymphoid Cancers
Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing ...
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response (pCR) in almost half of patients with stage I to III mismatch repair–deficient (dMMR) colon...
Inflammatory Breast Cancer: Blood-Based Biomarkers Identified
Researchers have identified blood-based biomarkers in tumors, peripheral blood cells, and plasma that may help to differentiate between inflammatory breast cancer and non–inflammatory breast cancer, according to findings published in Science Advances. “These findings provide new insights into...
Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer
A new urine test performed better than prostate specific antigen (PSA)-based testing and magnetic resonance imaging (MRI) for monitoring patients with low-risk prostate cancer on active surveillance. Use of the test to determine the need for repeat “monitoring” biopsies would have avoided up to 64% ...
Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults
In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United States in recent years. Study Details The population-based study used linked Surveillance...
B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD
In a phase II trial reported in the Journal of Clinical Oncology, Cutler et al found that early B-cell depletion with obinutuzumab reduced the risk of corticosteroid-requiring chronic graft-vs-host disease (GVHD) in allogeneic transplant recipients at increased risk of chronic GVHD. Study Details...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
From Hawaii to Health AI: A Career at the Intersection of Oncology, Data Science, and Clinical Knowledge
Raised in Lahaina, Hawaii, before wildfires destroyed much of the small tourist town in 2023, Travis Zack, MD, PhD, took an atypical path into medicine. His journey has been shaped by family, mentors, a personal experience with cancer, and a growing interest in how artificial intelligence (AI) can...
Long-Term Risks Revealed for Older Survivors of Childhood Cancers
Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report published in the Journal of Clinical Oncology.1 When compared with the general population or sibling ...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on patient anxiety and clinician workload. The performance of the model was assessed in a...
De-escalation, Recovery, and Robotic Surgery in Breast Cancer Care
At the American Society of Breast Surgeons (ASBrS) 27th Annual Meeting, investigators presented new findings on breast cancer surgery, postoperative recovery, and radiation treatment planning. Among the many sessions, several studies were presented during a media briefing earlier this month and are ...
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
In an analysis of a single-center trial reported in a research letter in JAMA Oncology, Reiss et al identified long-term outcomes with rucaparib maintenance in patients with platinum-sensitive advanced pancreatic ductal adenocarcinoma (PDAC) with BRCA1, BRCA2, or PALB2 germline or somatic...
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing Cytoreductive Surgery
A retrospective study found that levels of commonly measured serum tumor markers—CEA, CA19-9, and CA125—can play a significant role in predicting outcomes in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy...
High YAP1 Expression Leads to Chemotherapy Resistance, Relapse in Treated SCLC
Expression of the YAP1 protein following treatment with chemotherapy is associated with the development of treatment resistance and cancer relapse in patients with small cell lung cancer (SCLC), according to findings from an analysis published in Journal of Thoracic Oncology. The researchers...
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Breast Density Reduction: Endoxifen vs Tamoxifen
Low doses of the investigational agent endoxifen reduced breast density to the same extent as the standard treatment tamoxifen, with fewer adverse events, according to results from the KARISMA study, a proof-of-principle, dose-determining, double-blinded, randomized, placebo-controlled trial. These ...
Advanced CKM Syndrome Associated With Greater Cancer Risk
Advanced cardiovascular-kidney-metabolic (CKM) syndrome may be associated with an increased risk of developing cancer, according to findings from a Japanese study published in Circulation: Population Health and Outcomes. “The study findings suggest that it is important to consider not only...
Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intravenous (IV) oxaliplatin, both combined with fluorouracil/leucovorin (LV5FU2), after curative-intent...
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by...
Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma
High objective response and complete response rates were observed with treatment with brentuximab vedotin and nivolumab in combination with doxorubicin and dacarbazine chemotherapy in patients with early-stage classical Hodgkin lymphoma, according to the results of a phase II trial published in...
On-Treatment PSA and Overall Survival in Prostate Cancer
In a post hoc analysis reported in The Lancet Oncology, Kayani et al found that on-treatment prostate-specific antigen (PSA) level was associated with overall survival in patients with metastatic or very high-risk nonmetastatic prostate adenocarcinoma from five phase III trials in the STAMPEDE...
